Analyst Price Targets — ARVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 12:21 pm | — | Morgan Stanley | $10.00 | $8.94 | TheFly | Arvinas price target lowered to $10 from $11 at Morgan Stanley |
| August 10, 2026 12:14 pm | — | Evercore ISI | $14.00 | $8.95 | TheFly | Arvinas price target lowered to $14 from $19 at Evercore ISI |
| August 5, 2026 11:55 am | Robert Driscoll | Wedbush | $12.00 | $9.00 | TheFly | Arvinas price target raised to $12 from $11 at Wedbush |
| August 4, 2026 5:16 pm | — | Wells Fargo | $11.00 | $8.86 | TheFly | Wells downgrades Arvinas to Equal Weight, sees catalysts coming in 2027 |
| May 13, 2026 11:15 am | — | BTIG | $18.00 | $9.57 | TheFly | Arvinas price target raised to $18 from $16 at BTIG |
| May 13, 2026 8:57 am | — | Barclays | $20.00 | $9.57 | TheFly | Arvinas price target raised to $20 from $18 at Barclays |
| March 18, 2026 3:18 pm | Srikripa Devarakonda | Truist Financial | $10.00 | $10.96 | StreetInsider | Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data |
| February 24, 2026 7:02 pm | — | Wedbush | $11.00 | $12.37 | TheFly | Arvinas price target raised to $11 from $9 at Wedbush |
| December 17, 2025 10:54 am | — | Barclays | $18.00 | $11.90 | TheFly | Arvinas price target raised to $18 from $16 at Barclays |
| October 30, 2025 10:05 am | Jeet Mukherjee | BTIG | $14.00 | $9.59 | StreetInsider | Arvinas Inc. (ARVN) PT Raised to $14 at BTIG |
Latest News for ARVN
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in…
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (NASDAQ: ARVN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 167,056 shares of the company's stock, valued at approximately $1,388,000. Connor
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals. President and Chief Executive Officer Randy Teel said Rigel expects
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARVN.
U.S. House Trading
No House trades found for ARVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.